Preliminary Research on the Expression of Suppressor of Cytokine Signaling in Peripheral Blood Leukocytes of Polymyositis Patients_West China Medical Journal

Authors：

SUN Yuechi ¹ , DENG Lin ² , SUN Wencui ² , WU Yongqiang ² ,  SHI Guixiu ^1,2

1. Division of Rheumatology; 2. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

SHI Guixiu, Email: sunyuechi09@126.com

Keywords：

细胞因子信号转导蛋白抑制因子; 细胞因子诱导的含SH2区域蛋白; 多发性肌炎

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　研究活动期多发性肌炎患者外周血白细胞细胞因子信号转导蛋白抑制因子（SOCS）1、SOCS2、SOCS3和细胞因子诱导的含SH2区域蛋白1（CIS）与正常人表达的差异，探讨SOCS在多发性肌炎发病中可能的作用。方法　2011年6月－12月，采用实时荧光定量聚合酶链反应法检测了14例活动期多发性肌炎患者和14例正常人外周血白细胞中SOCS1、SOCS2、SOCS3和CIS1基因的相对表达量。结果　与对照组相比，多发性肌炎症患者外周血白细胞基因SOCS 1～3表达明显降低（P值均＜0.05），CIS1基因的表达较对照组明显升高（P＜0.05），差异有统计学意义。结论　SOCS基因家族可能参与了多发性肌炎的发病，该蛋白分子家族的成员可能会成为多发性肌炎治疗的一种新的候选基因。

Citation： SUN Yuechi,DENG Lin,SUN Wencui,WU Yongqiang,SHI Guixiu. Preliminary Research on the Expression of Suppressor of Cytokine Signaling in Peripheral Blood Leukocytes of Polymyositis Patients. West China Medical Journal, 2012, 27(4): 481-484. doi: Copy

1.	Lundberg IE. New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies[J]. Curr Opin Rheumatol, 2002, 14(6): 639-642.
2.	Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling[J]. Nature, 1997, 387(6636): 917-921.
3.	Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases[J]. Nature, 1997, 387(6636): 921-924.
4.	Yoshimura A, Nishinakamura H, Matsumura Y, et al. Negative regulation of cytokine signaling and immune responses by SOCS proteins[J]. Arthritis Res Ther, 2005, 7(3): 100-110.
5.	Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system[J]. Nat Rev Immunol, 2002, 2(6): 410-416.
6.	Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response[J]. Annu Rev Immunol, 2004, 22: 503-529.
7.	Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity[J]. Nat Immunol, 2003, 4(12): 1169-1176.
8.	Bohan A, Peter JB.Polymyositis and dermatomyositis (second of two parts) [J]. N Engl J Med, 1975, 292(8): 403-407.
9.	Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts) [J]. N Engl J Med, 1975, 292(7): 344-347.
10.	Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies[J]. Rheumatology (Oxford), 2001, 40(11): 1262-1273.
11.	Hanada T, Kinjyo I, Inagaki-Ohara K, et al. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases[J]. Rev Physiol Biochem Pharmacol, 2003, 149: 72-86.
12.	Chan HC, Ke LY, Chang LL, et al. Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus[J]. Lupus, 2010, 19(6): 696-702.
13.	Isomaki P, Alanärä T, Isohanni P, et al. The expression of SOCS is altered in rheumatoid arthritis[J]. Rheumatology (Oxford), 2007, 46(10): 1538-1546.
14.	Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis[J]. J Rheumatol, 2005, 32(9): 1650-1653.
15.	李苏芬, 方敬爱, 孙艳艳, 等. 阿托伐他汀对糖尿病肾病大鼠肾组织中JAK/STAT信号通路及其抑制因子SOCS-1表达的影响[J]. 中国中西医结合肾病杂志, 2011, 12(9): 765-768.
16.	Veenbergen S, Bennink MB, Affandi AJ, et al. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis[J]. Ann Rheum Dis, 2011, 70(12): 2167-2175.
17.	Ramgolam VS, Markovic-Plese S. Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis[J]. J Signal Transduct, 2011, 2011: doi: IO.1155/2011/635721.
18.	Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation[J]. Blood, 1997, 89(9): 3148-3154.
19.	Tsao JT, Kuo CC, Lin SC. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients[J]. Clin Exp Med, 2008, 8(4): 179-185.

1. 　Lundberg IE. New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies[J]. Curr Opin Rheumatol, 2002, 14(6): 639-642.
2. 　Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling[J]. Nature, 1997, 387(6636): 917-921.
3. 　Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases[J]. Nature, 1997, 387(6636): 921-924.
4. 　Yoshimura A, Nishinakamura H, Matsumura Y, et al. Negative regulation of cytokine signaling and immune responses by SOCS proteins[J]. Arthritis Res Ther, 2005, 7(3): 100-110.
5. 　Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system[J]. Nat Rev Immunol, 2002, 2(6): 410-416.
6. 　Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response[J]. Annu Rev Immunol, 2004, 22: 503-529.
7. 　Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity[J]. Nat Immunol, 2003, 4(12): 1169-1176.
8. 　Bohan A, Peter JB.Polymyositis and dermatomyositis (second of two parts) [J]. N Engl J Med, 1975, 292(8): 403-407.
9. 　Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts) [J]. N Engl J Med, 1975, 292(7): 344-347.
10. 　Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies[J]. Rheumatology (Oxford), 2001, 40(11): 1262-1273.
11. 　Hanada T, Kinjyo I, Inagaki-Ohara K, et al. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases[J]. Rev Physiol Biochem Pharmacol, 2003, 149: 72-86.
12. 　Chan HC, Ke LY, Chang LL, et al. Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus[J]. Lupus, 2010, 19(6): 696-702.
13. 　Isomaki P, Alanärä T, Isohanni P, et al. The expression of SOCS is altered in rheumatoid arthritis[J]. Rheumatology (Oxford), 2007, 46(10): 1538-1546.
14. 　Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis[J]. J Rheumatol, 2005, 32(9): 1650-1653.
15. 　李苏芬, 方敬爱, 孙艳艳, 等. 阿托伐他汀对糖尿病肾病大鼠肾组织中JAK/STAT信号通路及其抑制因子SOCS-1表达的影响[J]. 中国中西医结合肾病杂志, 2011, 12(9): 765-768.
16. 　Veenbergen S, Bennink MB, Affandi AJ, et al. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis[J]. Ann Rheum Dis, 2011, 70(12): 2167-2175.
17. 　Ramgolam VS, Markovic-Plese S. Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis[J]. J Signal Transduct, 2011, 2011: doi: IO.1155/2011/635721.
18. 　Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation[J]. Blood, 1997, 89(9): 3148-3154.
19. 　Tsao JT, Kuo CC, Lin SC. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients[J]. Clin Exp Med, 2008, 8(4): 179-185.

West China Medical Journal

Preliminary Research on the Expression of Suppressor of Cytokine Signaling in Peripheral Blood Leukocytes of Polymyositis Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content